Side-by-side comparison of AI visibility scores, market position, and capabilities
$2.56B revenue 2024; Q2 2025 $631.9M (-1.6% YoY); 101-103M projected US members 2025; telehealth market leader; telehealth market $123.26B 2024 to $455.27B 2030; 46.58% North America share
Teladoc Health is the world's largest telehealth company, founded in 2002 and headquartered in Purchase, New York, that pioneered on-demand virtual healthcare delivery in the United States. The company was founded on the premise that patients should be able to access physicians anytime and anywhere without traveling to a physical office — a model that took over a decade to gain mainstream acceptance before becoming a necessity during the COVID-19 pandemic. Teladoc's mission is to provide whole-person virtual care that addresses physical health, mental health, and chronic condition management through an integrated digital platform.\n\nTeladoc's platform encompasses general medical, dermatology, nutrition, and specialty care through its core telehealth offering; mental health and therapy through BetterHelp, the world's largest online therapy platform; virtual primary care and chronic condition management through Teladoc Primary360; and complex care navigation through its integrated whole-person health approach. The company serves employers, health plans, hospitals, and health systems, delivering virtual care to members across the US and internationally. BetterHelp has become a significant consumer-facing revenue driver, connecting individuals directly with licensed therapists without employer or insurance intermediaries.\n\nTeladoc reported $2.56 billion in revenue for 2024 and projects 101 to 103 million US members in 2025. The company trades on the NYSE under TDOC and holds a substantial lead in telehealth market share through its scale, multi-specialty breadth, and direct-to-consumer mental health reach via BetterHelp. Despite post-pandemic normalization and the $13.7 billion Livongo write-down in 2022, Teladoc remains the largest and most diversified virtual care platform, with continued investment in AI-powered clinical decision support and chronic disease management to drive the next phase of growth.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.